Japan news from FiercePharma
NewsSciele enjoys six-year stock high
After yesterday's news hit that Atlanta-based Sciele Pharma would accept Japan's Shionogi's generous buyout offer, shares of the drug company's stocks jumped nearly 60 percent. The deal, for $31 per... Read more...
Japanese pharma to pay $1.4B for Sciele
In yet another Japanese pharma takeover, Shionogi has agreed to pay $1.42 billion for the Atlanta-based drugmaker Sciele Pharma. That's a $31-per-share cash offer, a 61 percent premium over Sciele's... Read more...
Teva seeks venture partner in Japan
Fresh off its $7.5 billion deal to buy Barr Pharmaceuticals, Teva is eyeing joint ventures in Japan. CEO Shlomo Yanai told the Financial Times that establishing a beachhead in that country is a top... Read more...
Roche warns of Tamiflu psych effects
After some arm-twisting from the FDA, Roche has added stronger warnings to its Tamiflu label. In a Dear Healthcare Professional letter, the company cautioned doctors about the sometimes-fatal... Read more...
Japan changes scrips to favor generics
The tidal wave of generics has reached Japan. That country's government has proposed changes to prescription forms that would promote use of cheaper generics. Japanese copycat-drug companies saw... Read more...
SPOTLIGHT: Merck KGaA leads team to sell Erbitux in Japan
Merck KGaA leads team to sell Erbitux in Japan Call it a trifecta: ImClone Systems, Bristol-Myers Squibb and Merck KGaA are joining together to develop and market ImClone's cancer drug Erbitux in... Read more...
It's Merck v. Glaxo in vaccine battle
Call it the battle of the HPV vaccines. For the past week, either Merck's Gardasil or GlaxoSmithKline's Cervarix--or both--have captured headlines: • Glaxo submits Cervarix for approval in Japan... Read more...
Pfizer plots spinoff of Japanese R&D
Saved by the spinoff. Pfizer is looking to set up its Japanese R&D operation, previously slated for shutdown, as an independent company--with the help of a few investors, of course. The company... Read more...
| Press ReleasesMedImmune Licenses Reverse Genetics Technology to Japan's BIKEN for Use in Influenza Vaccine Development and ProductionMedImmune Licenses Reverse Genetics Technology to Japan's BIKEN for Use in Influenza Vaccine Development and Production GAITHERSBURG, Md., Sept 29, 2008 /PRNewswire via COMTEX News Network/ -- Read more >> Merck & Co., Inc. (MRK) (JOBS), Japan Tobacco in Osteoporosis Drug DealMerck & Co., Inc. (MRK) (JOBS), Japan Tobacco in Osteoporosis Drug Deal September 25, 2008 WHITEHOUSE STATION, N.J. & TOKYO--(BUSINESS WIRE)--Merck & Co., Inc. and Japan Tobacco Inc. (JT) Read more >> Teva and Kowa Announce Strategic Partnership to Create a Leading Generic Pharmaceutical Company in JapanTeva and Kowa Announce Strategic Partnership to Create a Leading Generic Pharmaceutical Company in Japan Goal to Reach Sales of $1 Billion in 2015 Jerusalem, Israel, and Tokyo, Japan, September 24, Read more >> |
Get more Japan coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
